Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Phasebio Pharmaceuticals Inc
(NQ:
PHAS
)
0.0701
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Nov 2, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phasebio Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
April 07, 2022
Gainers Trevi Therapeutics (NASDAQ:TRVI) stock rose 45.8% to $2.77 during Thursday's regular session. Trevi Therapeutics's stock is trading at a volume of 15.2...
Via
Benzinga
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
April 04, 2022
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
February 14, 2022
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 01, 2022
Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market value of their outstanding shares is at $18.4...
Via
Benzinga
53 Biggest Movers From Yesterday
March 30, 2022
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 29, 2022
Gainers IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM Biosciences's stock is trading at a volume of 31.6 million...
Via
Benzinga
Looking Into PhaseBio Pharmaceuticals's Return On Capital Employed
March 25, 2022
Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from...
Via
Benzinga
63 Biggest Movers From Yesterday
March 25, 2022
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet...
Via
Benzinga
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
March 24, 2022
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
58 Biggest Movers From Yesterday
March 24, 2022
Gainers Allego N.V. (NYSE: ALLG) shares surged 114.1% to close at $17.73 on Wednesday after the company announced the completion of its merger agreement with Spartan Acquisition...
Via
Benzinga
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
February 24, 2022
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
February 15, 2022
Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
52 Weeks High And Low Article
February 11, 2022
On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company...
Via
Benzinga
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
February 10, 2022
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
December 21, 2021
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The...
Via
Benzinga
PhaseBio Provides Pemziviptadil (PB1046) Program Update
December 21, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
February 08, 2022
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap...
Via
Benzinga
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
December 01, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
November 29, 2021
Gainers Cumberland (NASDAQ:CPIX) share...
Via
Benzinga
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
November 18, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 17, 2021
Gainers Rani Therapeutics Hldgs (NASDAQ:RA...
Via
Benzinga
70 Biggest Movers From Yesterday
November 16, 2021
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...
Via
Benzinga
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
November 15, 2021
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of...
Via
Benzinga
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
November 15, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
November 10, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
November 10, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
November 03, 2021
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The...
Via
Benzinga
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
November 03, 2021
From
PhaseBio Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.